Identification of pediatric MASLD using insulin resistance indices.

Background & Aims: We investigated the triglyceride-to-high density lipoprotein (HDL) ratio (TG/HDL), triglyceride-glucose index (TyG), single-point insulin sensitivity estimator (SPISE), and metabolic score for insulin resistance (METS-IR) as potential predictors of pediatric metabolic dysfunction-associated steatotic liver disease (MASLD) by addressing the limited research on insulin-resistance markers in this population. Methods: This cross-sectional study included data from 1,150 and 260 youths from the National Health and Nutrition Examination Survey (NHANES) and a real-world clinic, respectively. Hepatic steatosis was assessed using transient elastography and abdominal sonography. Logistic regression analysis was performed using MASLD as the dependent variable. Receiver operating characteristic (ROC) curves were used to evaluate predictability. Results: The MASLD group had higher TG/HDL, TyG, METS-IR, and obesity proportions but lower SPISE than the normal group in both NHANES and real-world data. All markers were significantly related to MASLD in logistic regression analyses, even after adjusting for age and sex, in both the NHANES and real-world clinic data (all Conclusions: METS-IR and SPISE are effective, non-invasive markers for predicting pediatric MASLD, which offer valuable tools for early detection and improved clinical management. Impact and implications: The increasing prevalence of pediatric metabolic dysfunction-associated steatotic liver disease (MASLD) and its strong association with cardiometabolic risk factors underscore the need for effective early detection tools. Our study demonstrates that single-point insulin sensitivity estimator (SPISE) and metabolic score for insulin resistance (METS-IR) are superior, non-invasive markers for predicting MASLD in children and adolescents, with validated cut-off values applicable to both population-based and real-world clinical settings. These findings are particularly relevant for clinicians and healthcare policymakers, as they provide practical, easily accessible screening tools derived from routine laboratory tests, aiding in the early identification and risk stratification of pediatric MASLD. However, given the study's retrospective design and variations in diagnostic methods across datasets, further validation in larger, diverse cohorts is warranted to refine age-specific cut-off values and optimize screening approaches.